Adapt Pharma has announced the availability of Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose in the US. Narcan nasal spray was approved by the FDA in November 2015. In 17 of the 50 US states, no prescription is required.
According to Adapt, the nasal spray will be available at a discounted price of $37.50 per dose for government agencies, non-profits, school districts, and institutes of higher education through the US Communities Cooperative Purchasing Program. High schools will be able to get a free carton of Narcan nasal spray thanks to a partnership with the Clinton Health Matters Initiative. Adapt also is also offering direct online sales through narcannasalspray.com.
Adapt Chairman and CEO Seamus Mulligan commented, “The US is facing an unprecedented opioid overdose epidemic, and we are grateful for the opportunity to officially provide the communities on the frontline of this battle a ready-to-use, needle-free, effective emergency treatment. Opioid overdoses can occur anywhere and at any time. By making Narcan Nasal Spray available, we hope to increase everyone’s access to emergency treatments across the US, when every second matters.”
Read the Adapt Pharma press release.
